Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02994459 · ClinicalTrials.gov registry record

Study of Fat Tissue's Ability to Take up Sugar in the Obese Population

A clinical trial of Glucose Metabolism Disorders, sponsored by University of Missouri-Columbia.

Active
Registry status
90
Enrollment target
1
Study location

NCT02994459 is a study of Glucose Metabolism Disorders that is active but no longer recruiting, run by University of Missouri-Columbia. The registered enrollment target is 90 participants, below the 224-participant average among 14 other Glucose Metabolism Disorders trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02994459, a study of Glucose Metabolism Disorders, is active but no longer recruiting, sponsored by University of Missouri-Columbia.

ACTIVE NOT RECRUITING
Registry status
90 participants
Enrollment target
1
Study location

Study Summary

People who are obese often have insulin resistance (inability of insulin to properly control blood sugar) and high blood sugar. However, not all people with obesity have this problem. About one-third of people with obesity have normal sugar metabolism (the way your body uses sugar). Similarly, not all people who are lean are also metabolically healthy and a subset of people who are lean are referred to as metabolically abnormal lean (MAL) or metabolically obese lean because they have the abnormalities in glucose metabolism typically associated with obesity. The reasons why some people with obesity have a problem with blood sugar control and others do not are not entirely clear. It is thought that impaired muscle sugar uptake is the main problem related to high blood sugar in people with obesity. However, adipose tissue (fat tissue) also consumes a substantial amount of blood sugar. Therefore, it is unclear whether muscle or adipose tissue (fat tissue) are primarily responsible for altered blood sugar concentrations in persons with metabolically abnormal obesity (MAO) (those with insulin resistance), compared to those with metabolically normal (healthy) obesity (MNO), or whether "healthy" adipose tissue (fat tissue) expansion in MNO people compared with lean people provides a vessel for blood sugar removal that helps maintain normal blood sugar concentration. Accordingly, the investigators will determine the amount of sugar that is taken up by the body and in the cells of adipose tissue (fat tissue) and muscle by infusing labeled sugar into the blood and looking at its disappearance from blood and appearance in adipose tissue (fat tissue) and muscle. The investigators will also determine how well insulin, a hormone that controls blood sugar, turns on signals that stimulate sugar uptake in fat and muscle cells. These studies will be done after an overnight fast and during an infusion of sugar and insulin (hyperinsulinemic-euglycemic clamp), in sex- and age-matched pe

Interventions

  • OTHER Weight Loss

Study Locations (1)

Missouri

  • Washington University School of Medicine - St Louis

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2017-07-01
Est. Completion 2027-01

Sponsor

University of Missouri-Columbia

291 total trials

What the Registry Record Tells You About NCT02994459

The ClinicalTrials.gov registry entry for NCT02994459 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 224-participant average among 14 other Glucose Metabolism Disorders trials with a reported enrollment target (60% lower). The listed sponsor is University of Missouri-Columbia, which has 291 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Glucose Metabolism Disorders appearing as the primary indexed condition, and to 1 intervention - of which Weight Loss is the first listed.

NCT02994459 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.

Frequently Asked Questions

What is clinical trial NCT02994459 about?

NCT02994459 is a clinical study titled "Study of Fat Tissue's Ability to Take up Sugar in the Obese Population". People who are obese often have insulin resistance (inability of insulin to properly control blood sugar) and high blood sugar. However, not all people with obesity have this problem. About one-third of people with obesity have normal sugar metabolism (the way your body uses sugar). Similarly, not a...

What is the current status of trial NCT02994459?

This trial is currently active not recruiting. The enrollment target is 90 participants. The study started on 2017-07-01. Estimated completion is 2027-01.

What conditions does trial NCT02994459 study?

This clinical trial studies the following conditions: Glucose Metabolism Disorders.

What interventions are being tested in trial NCT02994459?

The interventions under investigation include: Weight Loss (OTHER).

Who is sponsoring clinical trial NCT02994459?

This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02994459 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Glucose Metabolism Disorders

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.